I. van Praagh

发表

Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments

Y. Boirie, M. Duclos, A. Ginzac, 2018, Clinical breast cancer.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

S. Mathoulin-Pélissier, I. van Praagh, V. Girre, 2014, PloS one.

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

I. van Praagh, C. Abrial, F. Kwiatkowski, 2021, Cancer medicine.

Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

M. Mouret-Reynier, P. Dubray-Longeras, I. van Praagh, 2015, Oncology.

Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.

F. Penault-Llorca, I. van Praagh, C. Abrial, 2005, The oncologist.

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.

S. Schraub, M. Namer, J. Bonneterre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paracervical block anesthesia in labour.

I. van Praagh, W. G. Povey, 1966, Canadian Medical Association journal.

Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer

M. Mouret-Reynier, I. van Praagh, X. Durando, 2009, Expert opinion on pharmacotherapy.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

F. Penault-Llorca, N. Radosevic-Robin, T. Petit, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and pathological response to primary chemotherapy in operable breast cancer.

S Charrier, M. D. De Latour, I. van Praagh, 1997, European journal of cancer.

Perforation of a puerperal uterus with two Lippes loops.

I. van Praagh, D. Murdoch, G. Munsick, 1969, American journal of obstetrics and gynecology.

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.

F. Penault-Llorca, M. Mouret-Reynier, I. van Praagh, 2002, International journal of oncology.

Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors

M. Mouret-Reynier, I. van Praagh, F. Kwiatkowski, 2012, Oncology.

Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.

M. D. De Latour, I. van Praagh, P. Chollet, 2002, The oncologist.

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.

B. Weber, M. Campone, I. van Praagh, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

F. Penault-Llorca, N. Radosevic-Robin, M. Mouret-Reynier, 2016, International journal of cancer.

Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.

J. Abrahámová, I. van Praagh, E. Simova, 2001, The oncologist.

Pre- and Postoperative Aminoacidemia in Breast Cancer: A Study vs. Matched Healthy Subjects

B. Beaufrère, M. Vasson, I. van Praagh, 2004, Cancer investigation.

401PEVEROLIMUS PLUS HORMONOTHERAPY (HT) INDUCES SURVIVAL GAIN IN LATE METASTATIC BREAST CANCER (MBC) AFTER PROGRESSION: COULD THIS LINE BE BETTER THAN A LATE NEW CHEMOTHERAPY (CT) LINE?

M. Mouret-Reynier, P. Dubray-Longeras, I. van Praagh, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Paracervical Block Anesthesia for Dilatation and Curettage

I. van Praagh, W. G. Povey, 1967, Obstetrics and gynecology.

The use of paracervical block anesthesia for dilatation and curettage.

I. van Praagh, W. G. Povey, 1966, Canadian Medical Association journal.

[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].

M. Mouret-Reynier, I. van Praagh, C. Abrial, 2006, Bulletin du cancer.